Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04099277 · OUTCOME

Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR)

A Study of LY3435151 in Participants With Solid Tumors · Source last updated 2021-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline through Disease Progression or Death (Up to 4 Months)

What was measured

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.

Analysis population: Zero participants were analyzed. The study was terminated early and no data was collected.

Groups in this outcome

10 mg LY3435151

Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
10 mg LY34351510

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.
groups
  1. description
    Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.
    id
    OG000
    title
    10 mg LY3435151
population Description
Zero participants were analyzed. The study was terminated early and no data was collected.
reporting Status
POSTED
time Frame
Baseline through Disease Progression or Death (Up to 4 Months)
title
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice